News | March 19, 2012

National Physical Laboratory Purchases Nucletron's Brachytherapy Afterloader

March 19, 2012 -- The National Physical Laboratory (NPL), the United Kingdom's national measurement institute, recently purchased a Flexitron afterloader from Nucletron, an Elekta company. NPL will continue to offer its brachytherapy calibration service with the new afterloader and ensure source calibrations in radiotherapy centers remain traceable to NPL's primary standard.

"We chose Flexitron because it is a highly advanced brachytherapy platform that met all our requirements, offering the accuracy necessary to achieve the scientific excellence we strive for," says Thorsten Sander, senior research scientist at NPL. "Flexitron also provides us the opportunity to collaborate in the development of new technologies, to expand brachytherapy products and applications."

Nucletron and NPL have collaborated since 1992.

Flexitron is an advanced afterloader that takes brachytherapy to a new level. With robust safety features and flexible 40-channel configuration, Flexitron is designed to treat both very small and very large tumors without reconnections in intuitive 1 mm steps.

Accurate determination of source positions is simplified and reliability is enhanced with Nucletron's zero reference source positioning system, which defines dwell positions in absolute values. This significantly reduces the chance of human error; no additional measures or manual recalculations are required. Procedures take less time and are easier to check. Flexitron patented source drives are more precise and
durable than ever, providing reliable treatment from year to year.

For more information:,

Related Content

Varian Showcases Advanced Cancer Care Solutions at AAPM 2018
News | Radiation Therapy | July 27, 2018
Varian announced it will be showcasing its advanced cancer care solutions, including a new version of the Eclipse...
Florida Hospital First in State to Adopt NeuroLogica's BodyTom Elite CT
News | Computed Tomography (CT) | June 14, 2018
June 14, 2018 — NeuroLogica, a subsidiary of Samsung Electronics Co.
IsoRay Funding Brain Cancer Treatment Research With Ochsner Clinic Foundation
News | Brachytherapy Systems | June 12, 2018
IsoRay Inc. announced the initiation of research funding for brain cancer treatment to Ochsner Clinic Foundation, a not...
News | Brachytherapy Systems | June 07, 2018
IsoRay Inc. announced the upcoming release of its Build-Blu delivery system for real-time prostate brachytherapy.
Combination Radiotherapy Beneficial in Treating Prostate Cancer
News | Prostate Cancer | March 27, 2018
March 27, 2018 — While there are many treatment options for men with...
​ITN Celebrates World Cancer Day 2018
News | Radiation Oncology | February 01, 2018
World Cancer Day takes place annually on Feb.
California US Oncology Network Centers Adopt Xoft Electronic Brachytherapy System for Early-Stage Non-Melanoma Skin Cancer
News | Brachytherapy Systems | January 02, 2018
iCAD Inc. announced that its Xoft Axxent Electronic Brachytherapy (eBx) System is now available at two California-based...
Intraoperative Radiotherapy Provides Lifetime Cost Savings, Health Benefits for Early-Stage Breast Cancer Treatment
News | Brachytherapy Systems, Women's Healthcare | December 19, 2017
iCAD Inc. announced the results of a landmark study that showed the benefits of adjunct intraoperative radiation...
Xstrahl Photoelectric Therapy System Receives FDA 510(k) Clearance
Technology | Radiation Therapy | October 20, 2017
Xstrahl announced that its Photoelectric Therapy System has received U.S. Food and Drug Administration (FDA) 510(k)...
News | Brachytherapy Systems | October 05, 2017
External researchers presented new clinical data supporting the use of iCAD’s Xoft Axxent Electronic Brachytherapy (eBx...
Overlay Init